(ANSA) - BRUSSELS, JUN 17 - "Based on past experiences", mixing vaccines "seems a strategy that can be used, but there is limited evidence on Covid-19 ones and it is important to collect more information and monitor carefully". Thus Marco Cavaleri of the Ema.
"From an EMA perspective, it is not easy at this stage to make a clear recommendation" on the mix of Covid vaccines, "also because it is not clear whether the company has an interest in requesting authorization to add information on the product". But as soon as we have more data, for example from the British studio, we will consider whether to make a statement on the mix ". (ANSA).